Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab continuation after progression in advanced NSCLC (China)
ChiCTR2500109648Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Henan Cancer Hospital. Primary endpoint: Overall survival. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500109648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109648.